Laurel Wealth Advisors LLC Sells 4,575 Shares of Pfizer Inc. (NYSE:PFE)

Laurel Wealth Advisors LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 25.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 13,266 shares of the biopharmaceutical company’s stock after selling 4,575 shares during the period. Laurel Wealth Advisors LLC’s holdings in Pfizer were worth $382,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Coerente Capital Management grew its holdings in shares of Pfizer by 0.5% during the third quarter. Coerente Capital Management now owns 547,205 shares of the biopharmaceutical company’s stock valued at $18,151,000 after buying an additional 2,865 shares during the last quarter. Verity & Verity LLC grew its holdings in shares of Pfizer by 9.6% during the third quarter. Verity & Verity LLC now owns 445,117 shares of the biopharmaceutical company’s stock valued at $13,981,000 after buying an additional 39,133 shares during the last quarter. McGlone Suttner Wealth Management Inc. grew its holdings in shares of Pfizer by 4.7% during the third quarter. McGlone Suttner Wealth Management Inc. now owns 13,388 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 596 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its holdings in shares of Pfizer by 16.3% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 26,335 shares of the biopharmaceutical company’s stock valued at $874,000 after buying an additional 3,686 shares during the last quarter. Finally, Asset Planning Services Inc. LA ADV grew its holdings in shares of Pfizer by 2.8% during the third quarter. Asset Planning Services Inc. LA ADV now owns 125,453 shares of the biopharmaceutical company’s stock valued at $4,161,000 after buying an additional 3,375 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on PFE shares. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $36.33.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.14 on Friday, hitting $25.40. 46,526,457 shares of the company’s stock were exchanged, compared to its average volume of 34,120,812. The company has a 50-day simple moving average of $26.96 and a 200-day simple moving average of $28.36. The stock has a market capitalization of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.14 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.61%. Pfizer’s payout ratio is 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.